Belite Bio (NASDAQ:BLTE) executives said the company is advancing toward a potential U.S. approval decision for tinlarebant, its oral once-daily treatment for Stargardt disease, while also preparing for broader development in geographic atrophy. Speaking at the Bank of America Healthcare Conference, Chief Executive Officer Tom Lin described Belite as an ophthalmology- and retinal-focused company that […]